Status:
COMPLETED
Promoting Men's Adherence to BRCA1/2 Germline Genetic Testing
Lead Sponsor:
European Institute of Oncology
Conditions:
BRCA1 Mutation
BRCA2 Mutation
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
BRCA1- and BRCA2-associated Hereditary Breast and Ovarian Cancer Syndrome (HBOC) increases the relative and absolute risk of developing breast and ovarian cancer and, to a lesser extent, prostate and ...
Detailed Description
Background As for other pathogenic gene mutations \[1,2\], germline mutations in BRCA1- and BRCA2 genes (BReast CAncer 1 gene and BReast CAncer 2 gene) predispose carriers to an increased suscepti-bil...
Eligibility Criteria
Inclusion
- Male relatives of patients with an established germline genetic mutation (pathogenic or likely pathogenic variants) of the BRCA1 and / or BRCA2 genes
- Aged ≥ 18
- Able to give informed consent
- Able to read, speak, and understand Italian
Exclusion
- BRCA1 and / or BRCA2 germline genetic screening load detected
- Diagnosis of breast, pancreatic, or prostate cancer
Key Trial Info
Start Date :
January 10 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
264 Patients enrolled
Trial Details
Trial ID
NCT04683068
Start Date
January 10 2021
End Date
December 31 2021
Last Update
May 13 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
European Institute of Onocolgy
Milan, MI, Italy, 20141